Pulmonary Arterial Hypertension

The AJMC® Pulmonary Arterial Hypertension compendium is a comprehensive resource for clinical news and expert insights for the progressive disorder, which is characterized by high blood pressure in the arteries that go from the heart to the lungs.

Latest News

echocardiogram | Image Credit: © Pepermpron-stock.adobe.com
Echocardiographic Assessment Shows Promise as Risk Predictor in PAH

August 29th 2025

Close to 40% of patients with right heart failure and pulmonary arterial hypertension (PAH) who remain critically ill and require admittance to the intensive care unit die within 1 year of that hospitalization.

Tricuspid Regurgitation | Image Credit: © Richelle-stock.adobe.com
Tricuspid Regurgitation Reliable Prognostic Indicator of PAH Severity

August 13th 2025

Lungsandheart | Image Credit: Kiattisak-stock.adobe.com
Genetic Study Finds Hypothyroidism May Increase PAH Risk

July 25th 2025

Lung transplant | Image Credit: Pixel-Shot-stock.adobe.com
Lung Transplant Referrals Lag for High-Risk Patients With PAH

July 18th 2025

PAH | Image Credit: Maggie-sora.chatgpt.com
FDA Reviewing Sotatercept-csrk Label Expansion for PAH

July 14th 2025

Transforming PAH Management Through Innovation and Strategic Care

Learn how novel therapies, early diagnosis, and personalized treatment approaches are advancing PAH care while addressing clinical needs, patient preferences, and economic impact.

AJMC Stakeholder Summit logo displayed on a light blue and white scientific background with hexagonal molecular graphics and connecting lines.

More News

Monotherapy or Combo Therapy for Older Patients With PAH and Multiple Comorbidities?
April 30th 2021

Monotherapy or Combo Therapy for Older Patients With PAH and Multiple Comorbidities?

Laura Joszt, MA
Patients with pulmonary arterial hypertension (PAH) who have comorbidities or advanced age who are treated with a monotherapy have comparable outcomes to patients on combination therapies.
Text Messages Can Successfully Increase Step Counts for Patients With PAH
April 27th 2021

Text Messages Can Successfully Increase Step Counts for Patients With PAH

Laura Joszt, MA
A text message–based intervention successfully increased step counts for patients with pulmonary arterial hypertension (PAH).
Patients With PAH Can Safely Transition From Bosentan and Sildenafil to Alternative Therapy
April 21st 2021

Patients With PAH Can Safely Transition From Bosentan and Sildenafil to Alternative Therapy

Laura Joszt, MA
While bosentan and sildenafil is a common combination therapy in patients with pulmonary arterial hypertension (PAH), patients may need to transition to alternative therapy because of the potential for drug-drug interactions with this combination.
Educational Support Can Improve Compliance to Oral PAH Therapies
April 18th 2021

Educational Support Can Improve Compliance to Oral PAH Therapies

Laura Joszt, MA
An educational nursing program can positively impact medication compliance in patients receiving oral pulmonary arterial hypertension (PAH) therapies.
hospital hallway
April 15th 2021

PAH Treatment Patterns and Costs Related to Hospitalization

Laura Joszt, MA
New research presented at AMCP 2021, the annual meeting of the Academy of Managed Care Pharmacy, evaluated treatment patterns and costs related to hospitalization for patients with pulmonary arterial hypertension (PAH).
Better Understanding of Potential Genetic Mutations May Lead to Improved PAH Diagnosis, Treatment
April 13th 2021

Better Understanding of Potential Genetic Mutations May Lead to Improved PAH Diagnosis, Treatment

Laura Joszt, MA
A better understanding of the genetic etiology of pulmonary arterial hypertension and its molecular variants is needed to develop better therapies for the disease, which has no agents available that can reverse or halt it.
Assessing Nutritional Risk Can Predict PAH Prognosis at First Hospitalization
April 6th 2021

Assessing Nutritional Risk Can Predict PAH Prognosis at First Hospitalization

Laura Joszt, MA
Adjunct nutritional therapies may be a simple way to improve the prognosis for patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension who are hospitalized.
SPHERE Registry Provides Snapshot of Selexipag to Treat PAH in the Real World
April 5th 2021

SPHERE Registry Provides Snapshot of Selexipag to Treat PAH in the Real World

Laura Joszt, MA
Registry of patients with pulmonary arterial hypertension (PAH) treated with selexipag provides insights into real-world dosing regimens and outcomes.
Iron Replacement Has No Impact on Disease Severity, Quality of Life in PAH
April 1st 2021

Iron Replacement Has No Impact on Disease Severity, Quality of Life in PAH

Laura Joszt, MA
Idiopathic pulmonary arterial hypertension (PAH) is associated with iron deficiency, which is in turn associated with worse functional capacity and survival in PAH; however, iron repletion by infusion provided no significant clinical benefit.
Evaluating Efficacy of Initial Combination Therapy on Pulmonary Vascular Resistance
March 27th 2021

Evaluating Efficacy of Initial Combination Therapy on Pulmonary Vascular Resistance

Laura Joszt, MA
An ongoing multicenter study in Japan will evaluate reductions in pulmonary vascular resistance 8 months after initiating the combination therapy in pulmonary arterial hypertension.
blue heart and echocardiogram
March 21st 2021

Survey Finds Unmet Needs Despite Good HRQOL for Patients With PAH

Skylar Jeremias
Despite patients with pulmonary arterial hypertension reporting good quality of life and low symptom severity, functional limitations persisted, suggesting improvements to the patient experience are needed, according to researchers.
Patients With PAH Have Similar Incidence of COVID-19, but Potentially Worse Outcomes
March 18th 2021

Patients With PAH Have Similar Incidence of COVID-19, but Potentially Worse Outcomes

Laura Joszt, MA
Patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension had similar incidence of COVID-19, but the impact on clinical operations at the centers that treat these patients was substantial.
Nasal cannula for oxygen
March 9th 2021

Oxygen Has Potential Benefits as a Therapy for Pulmonary Arterial Hypertension

Laura Joszt, MA
A review of evidence finds that oxygen therapy may be beneficial for all patients with pulmonary arterial hypertension, not just those who develop severe hypoxemia.
Newly Diagnosed Patients With PAH Benefit From Earlier Initiation of Therapy
March 7th 2021

Newly Diagnosed Patients With PAH Benefit From Earlier Initiation of Therapy

Laura Joszt, MA
Patients with pulmonary arterial hypertension (PAH) who are treated with selexipag within 6 months of their diagnosis had a reduced risk of morbidity/mortality compared with patients who were treated longer than 6 months after diagnosis.
Pulmonary Arterial Capacitance Is a Strong Predictor of Mortality in PAH, PH-LHD
March 5th 2021

Pulmonary Arterial Capacitance Is a Strong Predictor of Mortality in PAH, PH-LHD

Laura Joszt, MA
Targeting pulmonary arterial capacitance or compliance can improve overall survival and quality of life in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension secondary to left heart disease (PH-LHD).
Real-World Study Finds Oral Combination Therapy of Macitentan, Riociguat, and Selexipag Effective in PAH
March 2nd 2021

Real-World Study Finds Oral Combination Therapy of Macitentan, Riociguat, and Selexipag Effective in PAH

Laura Joszt, MA
Triple oral combination therapy with macitentan, riociguat, and selexipag may be a promising strategy to treat patients with low/intermediate-risk pulmonary arterial hypertension (PAH), and possibly even patients with high-risk PAH.
Diagnosing and Treating Systemic Sclerosis With PAH Remains Challenging
February 27th 2021

Diagnosing and Treating Systemic Sclerosis With PAH Remains Challenging

Laura Joszt, MA
While diagnostic algorithms have evolved in the last decade, there remains an urgent need for innovative therapeutic options to treat systemic sclerosis with pulmonary arterial hypertension.
Understanding Mortality Risk in Pediatric Pulmonary Arterial Hypertension
February 26th 2021

Understanding Mortality Risk in Pediatric Pulmonary Arterial Hypertension

Larry Hanover
The study examined various factors used in an internationally developed risk stratification strategy to assess which ones had evidence of being significant in determining a child’s prognosis from the deadly disease.
Which Agents Are Linked to Drug- and Toxin-Induced PAH?
February 20th 2021

Which Agents Are Linked to Drug- and Toxin-Induced PAH?

Jaime Rosenberg
In their recently published review, the researchers offer a detailed look at the drugs and toxins associated with drug- and toxin-induced pulmonary arterial hypertension (PAH), as various associations have come to light in recent decades.
A Roadmap for Managing Right Ventricular Failure in PH
February 19th 2021

A Roadmap for Managing Right Ventricular Failure in PH

Jaime Rosenberg
The researchers prefaced their study by highlighting that pulmonary arterial hypertension (PAH) and all forms of PH continue to be highly morbid and sometimes fatal, particularly in cases requiring hospitalization in the intensive care unit.
Doctors consulting
February 12th 2021

Temporary Treatment With IV Selexipag Is Safe for Patients With PAH

Larry Hanover
A temporary switch from oral to intravenous (IV) selexipag is safe and well tolerated in the treatment of pulmonary arterial hypertension (PAH).
Case Study Describes Development of PAH During Multiple Myeloma Therapy
February 11th 2021

Case Study Describes Development of PAH During Multiple Myeloma Therapy

Larry Hanover
Patients being treated for multiple myeloma with carfilzomib should have cardiopulmonary screening and monitoring due to the risk of developing pulmonary arterial hypertension (PAH).
Machine Learning-Based Approach to CMR Imaging Analysis Proves Beneficial for PAH Diagnosis
February 5th 2021

Machine Learning-Based Approach to CMR Imaging Analysis Proves Beneficial for PAH Diagnosis

Jaime Rosenberg
The approach, the researchers say, allows for rapid and accurate diagnosis of pulmonary arterial hypertension (PAH) by analyzing cardiac magnetic resonance (CMR) images without manual image segmentation.
Researchers Highlight Progress, Remaining Unknowns in Genetics of PAH
January 30th 2021

Researchers Highlight Progress, Remaining Unknowns in Genetics of PAH

Jaime Rosenberg
As up to 1 in 3 patients with pulmonary arterial hypertension have unknown explanations for their disease and its pathobiology, a team of researchers is exploring the genetic architecture of pulmonary arterial hypertension (PAH).
Prevalence, Incidence of PAH in SSc Steady Over Time, Report Says
January 29th 2021

Prevalence, Incidence of PAH in SSc Steady Over Time, Report Says

Allison Inserro
The authors said this study included more up-to-date definitions of diagnosing pulmonary arterial hypertension (PAH), which is an increasing factor in deaths from systemic sclerosis (SSc).
Low SES, Patient Barriers Hinder PAH Exercise Rehab
January 22nd 2021

Low SES, Patient Barriers Hinder PAH Exercise Rehab

Gianna Melillo
Lower socioeconomic status (SES) and barriers related to the perceived need for exercise rehabilitation were associated with decreased referral to rehabilitation among patients with pulmonary arterial hypertension (PAH).
Ensuring a Path of Success for Drug Repurposing in PAH
January 14th 2021

Ensuring a Path of Success for Drug Repurposing in PAH

Jaime Rosenberg
Among the viewpoints offered by the authors to overcome barriers in solving unmet needs in pulmonary arterial hypertension (PAH) are preclinical pipelines for drug repurposing, working around challenges in early-stage trial design, and refining target selection and demonstration of engagement.
Identifying Predictors of Mortality for Adults With PAH, CHD
January 9th 2021

Identifying Predictors of Mortality for Adults With PAH, CHD

AJMC Staff
A recent study sought to examine the course of these patients after the age of 40, and to identify possible risk factors for a worse prognosis.
Researchers Identify Predictors of Pulmonary Hypertension Among Patients With MPNs
December 29th 2020

Researchers Identify Predictors of Pulmonary Hypertension Among Patients With MPNs

Laura Joszt, MA
Survival among patients with myeloproliferative neoplasm (MPN)–associated pulmonary hypertension (PH) is generally short, although the true prevalence of PH among these patients is poorly understood.
Woman and man on balance scale
December 26th 2020

Sex, Genetics, and the Relationship Between the Two in Pulmonary Arterial Hypertension

Jaime Rosenberg
Although research has cemented BMPR2 mutations as having associations with the development of pulmonary arterial hypertension, the germline mutations are not the only culprit.
<1
...
456789>

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo